


Date of Deposit:

09/22/04



JFW

I hereby certify under that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, with sufficient postage on the date indicated

Name: Nada Jain

Signature: [Handwritten Signature]

Docket No. 1010/0101US14

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Leo J. Romanczyk, et al.

Filed: February 17, 2004 Group Art Unit:

Serial No: 10/780,298 Examiner:

For: Compositions for, and Methods of, Anti-Platelet Therapy

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In order to comply with 37 CFR 1.97 and 1.98, attached hereto is a copy of Form PTO-1449 and copies of the documents listed thereon.

Applicants respectfully request the Examiner's consideration of the cited references and entry into the record of this application and that it be cited of record in the prosecution history of the present application by initialing Form PTO-1449 next to the document. Such initialing is requested even if the Examiner does not consider a cited document to be sufficiently pertinent to use in a rejection, or otherwise does not consider it to be prior art for any reason, or even if the Examiner does not believe that the guidelines for citation have been fully complied with. This is


requested so that each document becomes listed on the face of the patent issuing on the present application.

The present Information Disclosure Statement is being submitted in compliance with 37 CFR 1.56, but the citation of such document is not to be construed as an admission that such document is necessarily relevant or prior art. No representation is intended that the cited documents represent the results of a complete search, and it is anticipated that the Examiner, in the normal course of examination, will make an independent search and will determine the best prior art consistent with 37 CFR 1.104 and, in the course of each search, will review for relevance every document cited on the attached form even if not initialed.

The present Information Disclosure Statement has been submitted prior to the receipt of an Office Action in this application. Accordingly, no fee is due. However, in the event that a first Office Action was mailed on or before the date of submission of this disclosure statement, the Commissioner is hereby authorized to charge any fees to deposit Account No. 50-2549.

Date: September 13, 2004


Respectfully submitted,



Nada Jain

Reg. No. 41,431

NADA JAIN, P.C.
560 White Plains Road, Suite 460
Tarrytown, NY 10591
Telephone: (914) 333-0610
Fax: (914) 333-0615



INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	Serial No. 10/780,298
	Inventors: Leo J. Romanczyk, et al.
	Docket No. 1010/0101US14

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	1.	5,720,956	2/24/98	Rohdewald	424	770	4/10/96

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION
	2.	JP02184626	7/19/90	JP	Yes/Abstract

OTHER DOCUMENTS

EXAMINER INITIAL		AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.
	3.	Chang, Wen-Chang and Hsu, Feng-Lin, <i>Inhibition of Platelet Aggregation and Arachidonate Metabolism in Platelets by Procyanidins, Prostaglandins Leukotrienes and Essential Fatty Acids</i> , Vol. 38, pp. 181-188 (1989)
	4.	Polette, A., et al., <i>N-3 Fatty Acid-induced Lipid Peroxidation in Human Platelets is Prevented by Catechins</i> , <i>Thromb. Haemost.</i> , Vol. 75, No. 6, pp. 945-949 (1996)
	5.	Kelly, Collete, et al., <i>Modulation of Human Platelet Function by Food Flavonoids</i> , <i>Biochemical Society Transactions</i> 24:197S (1996)
	6.	Uchida, Shinji, et al., <i>Inhibitory Effects of Condensed Tannins on Angiotensin Converting Enzyme</i> , <i>Japan. J. Pharmacol.</i> 43:242-246 (1987)
	7.	Chang, W.C., et al., <i>Inhibition of Platelet Activation and Endothelial Cell Injury by Flavan-3-ol and Saikosaponin Compounds</i> , <i>Prostaglandins Leukotrienes and Essential Fatty Acids</i> (1991)
	8.	Ferrandiz, M.L., et al., <i>Inhibition of Sheep Platelet Arachidonate Metabolism by Flavonoids from Spanish and Indian Medicinal Herbs</i> , <i>Pharmazie</i> 45, pp. 206-208 (1990)
	9.	Rohrbach, Michael S., et al., <i>Structural Determinants of the Platelet Agonist Activity of Cotton Bract Condensed Tannin</i> , <i>Environmental Research</i> 52:199-209 (1990)
	10.	Pace-Asciak, Cecil R., et al., <i>The Red Wine Phenolics trans-resveratrol and Quercetin Block Human Platelet Aggregation and Eicosanoid Synthesis: Implications for Protection Against Coronary Heart Disease</i> , <i>Clinica Chimica Acta</i> 235:207-219 (1995)
	11.	Pace-Asciak, Cecil R., et al., <i>Wines and Grape Juices as Modulators of Platelet Aggregation in Healthy Human Subjects</i> , <i>Clinica Chimica Acta</i> 246:163-182 (1996)
	12.	Van Acher et al., <i>Flavonoids as Scavengers of Nitric Oxide Radical</i> , <i>Biochem. Biophysical Res. Comm.</i> , 214: 755-759 (1995)

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	